Continuous infusion.
There is evidence, albeit scientifically weak, for improved cost/benefit with administration of factor concentrates by continuous infusion when high-dose replacement is necessary, as several studies have shown a reduced requirement for the concentrate. There is evidence from only one study for fewer bleeding complications with continuous infusion. There is evidence from two studies that additional therapy with tranexamic acid reduces the risk of bleeding complications in patients receiving continuous infusion. Future studies should address the question of minimum steady-state levels required for haemostasis, comparisons with bolus injection using a randomized design and investigate the risk of inhibitor formation.
Schulman
S
S
Department of Haematology, Coagulation Unit, Karolinska Hospital, Stockholm, Sweden. sam.schulman@ks.se
D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D001779:Blood Coagulation Factors / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005169:Factor VIII / Q000008:administration & dosage; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male
D001779:Blood Coagulation Factors; D005169:Factor VIII